-
1.发明申请Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme 审中-公开估计由施用化合物引起的药物不良反应的风险的方法，所述化合物本身由UGT1A1酶代谢或其代谢中间体被酶代谢公开(公告)号：US20070082357A1
公开(公告)日：2007-04-12
申请号：US11543055
申请日：2006-10-05
IPC分类号： C12Q1/68
CPC分类号： C12N9/1051 , C12Q1/6876 , C12Q2600/156
摘要： A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction, thereby reducing the adverse drug reaction cased by the administration of irinotecan.
摘要翻译： 评估由伊立替康的给药引起的不良药物反应的风险的估计方法; 以及减少由伊立替康给药引起的药物不良反应的方法。 基于外显子1的单核苷酸多态性，基于UGT1基因的启动子区域的TA重复序列的重复数和两种类型的多态性（211-和686位的碱基）的差异的多态性 被分析。 根据分析资料，估计伊立替康的施用引起药物不良反应的风险。 此外，根据不良药物反应的表达风险，为个体患者设计伊立替康的给药剂量，从而减少由伊立替康给药引起的药物不良反应。
-
2.发明申请Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme 审中-公开估计由施用化合物引起的药物不良反应的风险的方法，所述化合物本身由UGT1A1酶代谢或其代谢中间体被酶代谢公开(公告)号：US20090263818A1
公开(公告)日：2009-10-22
申请号：US12453291
申请日：2009-05-06
IPC分类号： C12Q1/68
CPC分类号： C12N9/1051 , C12Q1/6876 , C12Q2600/156
摘要： A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.
摘要翻译： 评价由伊立替康的给药引起的药物不良反应的风险的评价方法以及减少由伊立替康给药引起的不良药物反应的方法。 基于外显子1的单核苷酸多态性，基于UGT1基因的启动子区域的TA重复序列的重复数和两种类型的多态性（211-和686位的碱基）的差异的多态性 被分析。 根据分析资料，估计伊立替康的施用引起药物不良反应的风险。 此外，根据不利的drub反应的表达风险，为个体患者设计了伊立替康的给药剂量，从而减少了施用伊立替康引起的不良药物反应。
-
3.发明申请METHOD OF ESTIMATING THE RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY THE ADMINISTRATION OF A COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY THE ENZYME 审中-公开估计由化合物的施用引起的不良药物反应的风险的方法，每种化合物由UGT1A1酶代谢，或代谢中间体被酶代谢公开(公告)号：US20110151474A1
公开(公告)日：2011-06-23
申请号：US13026719
申请日：2011-02-14
IPC分类号： C12Q1/68
CPC分类号： C12N9/1051 , C12Q1/6876 , C12Q2600/156
摘要： A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.
摘要翻译： 评价由伊立替康的给药引起的药物不良反应的风险的评价方法以及减少由伊立替康给药引起的不良药物反应的方法。 基于外显子1的单核苷酸多态性，基于UGT1基因的启动子区域的TA重复序列的重复数和两种类型的多态性（211-和686位的碱基）的差异的多态性 被分析。 根据分析资料，估计伊立替康的施用引起药物不良反应的风险。 此外，根据不利的drub反应的表达风险，为个体患者设计了伊立替康的给药剂量，从而减少了施用伊立替康引起的不良药物反应。
-
-
搜索结果
3 条记录 (耗时 0.013 秒)
